Genetic diagnostics company GeneDx reported strong second-quarter 2025 financial results with revenues reaching $102.7 million, up 49% year-over-year. The growth was driven by a substantial 69% increase in revenues from whole-exome and whole-genome testing, which now accounts for 84% of total revenue. The company is capitalizing on updated American Academy of Pediatrics guidelines endorsing genome sequencing in general pediatrics, signaling further market expansion. Increased reimbursement rates and improved profitability also supported the upbeat financial performance. GeneDx continues to invest in R&D and operational scaling to capture broader clinical adoption across pediatrics and rare diseases.